CXCR2 and neoplasm: Furthermore, the intracellular CXCR2 (Supplementary Figure S1A) has been shown to activate the NFKB pathway in solid tumors [24], an action that releases different tumor-promoting cytokines to support the surviving blasts through bypassing the targeted therapy (indicated by a red dash arrow in schematic diagram of last figure).